Elevated CA 19-9 Levels in Patients

Clinical Significance

An elevated CA 19-9 level is concerning but not diagnostic for pancreatic or biliary tract malignancy, as this tumor marker can be elevated in multiple benign and malignant conditions, according to the National Comprehensive Cancer Network 1, 2
The American College of Gastroenterology recommends considering CA 19-9 levels in the context of other clinical and diagnostic findings, as elevated levels can be seen in up to 85% of patients with pancreatic cancer 3
The European Association for the Study of the Liver suggests that cholangiocarcinoma (bile duct cancer) can also cause elevated CA 19-9 levels 4

Moderate elevation (73.6 U/mL) is less specific for malignancy than values >100 U/mL, with values >100 U/mL having a sensitivity of 75% and specificity of 80% for cholangiocarcinoma in patients with primary sclerosing cholangitis (PSC) 4
The American Gastroenterological Association recommends evaluating for biliary obstruction, as CA 19-9 can be falsely elevated in benign biliary obstruction, and rechecking CA 19-9 after biliary decompression 1
Persistently elevated levels after biliary decompression are more concerning for malignancy, according to the National Institute of Diabetes and Digestive and Kidney Diseases 4

Contrast-enhanced CT and MRI with MRCP are recommended for evaluation of the pancreaticobiliary system, as suggested by the European Society of Gastrointestinal and Abdominal Radiology 5
Ultrasound is recommended as the first-line investigation for suspected biliary obstruction, according to the World Gastroenterology Organisation 4
Additional tumor markers (CEA, CA-125) should be considered, as no single marker is specific, as recommended by the American Society of Clinical Oncology 4

CA 19-9 is not recommended as a screening test for pancreatic cancer due to inadequate sensitivity and specificity, according to the American Cancer Society 6
False-negative results can occur in Lewis antigen-negative individuals (5-10% of population), as noted by the European Association for the Study of the Liver 5
CA 19-9 measurements using different testing methods cannot be directly compared, as stated by the National Comprehensive Cancer Network 1